RxDoctor Payments DataLook up a doctor →

Joel Vandersluis, MD

Neurology · Dayton, OHNPI 1114922390

Payments from drug & device makers

$12,349,505in general payments, 2019–2025

Across 1,301 payments — averaging $9492.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$8.8M
  • Novartis$2.2M
  • E.r. Squibb & Sons, L.L.C.$529K
  • AbbVie$231K
  • Eisai Inc.$178K
  • EMD Serono, Inc.$133K
  • plus $314K from 54 others
$31,450in research payments, 2019–2025

Across 11 payments — averaging $2859.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$31K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly63$8,759,889
Novartis116$2,204,332
E.r. Squibb & Sons, L.L.C.9$528,504
AbbVie(2 entities)112$231,243
Eisai Inc.116$178,380
EMD Serono, Inc.111$133,113
Takeda Pharmaceuticals U.S.A., Inc.40$96,199
Acadia Pharmaceuticals Inc30$57,333
Amgen(2 entities)19$40,706
Ipsen Innovation14$39,451
Biohaven Pharmaceuticals, Inc.31$34,970
Avanir Pharmaceuticals, Inc.5$13,075
Biohaven Pharmaceutical Holding Company Ltd.21$7,783
UCB SA1$7,085
Vertex1$6,036
Teva Pharmaceuticals USA, Inc.104$1,124
Ares Trading SA13$1,026
Neurocrine Biosciences, Inc.64$861
Biogen44$857
Lilly USA, LLC52$780
Pfizer43$694
MDD US Operations, LLC20$561
Genentech USA, Inc.25$478
Vanda Pharmaceuticals Inc.16$448
Sunovion Pharmaceuticals Inc.23$394
Bristol Myers Squibb14$341
Sanofi16$339
UCB, Inc.18$325
SK Life Science, Inc.16$300
Johnson & Johnson15$298
Argenx US, Inc.14$265
Neurelis, Inc.12$253
Lundbeck LLC11$208
Acorda Therapeutics, Inc8$121
Alnylam Pharmaceuticals Inc.7$119
Amneal Pharmaceuticals LLC7$118
Otsuka America Pharmaceutical, Inc.6$117
CSL Behring6$116
Arbor Pharmaceuticals, Inc.4$96
AstraZeneca(2 entities)5$95
Banner Life Sciences, LLC4$92
Adamas Pharmaceuticals, Inc.6$91
Novo Nordisk1$81
Springworks Therapeutics, Inc.3$72
Mallinckrodt Hospital Products Inc.2$61
Otsuka Pharmaceutical Development & Commercialization, Inc.2$60
GE HealthCare2$57
Axsome Therapeutics, Inc.2$51
Mallinckrodt Enterprises LLC2$51
Corium, LLC2$49
Avion Pharmaceuticals3$49
Supernus Pharmaceuticals, Inc.3$47
Octapharma USA, Inc.2$36
Aprecia Pharmaceuticals, LLC2$34
Nevro Corp.1$29
Bayer1$24
TG Therapeutics, Inc.1$24
Averitas Pharma Inc.1$23
Upsher-smith Laboratories LLC1$23
Impel Pharmaceuticals LLC1$19

How this compares

$12,349,505 in reported general payments places this provider in the 95th percentile of 702 neurology providers in Ohio.

See all neurology providers in Ohio →

Medicare billing

Part B allowed, 2024
$408,854
Medicare patients
534
Services billed
16,451

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Dayton

See the full list for Ohio →

Where these figures come from

Is this you, or does something look wrong? →